| Associated history or physical finding | Suspected conditions | Actions to consider |
|---|---|---|
| Abdominal cramping, attacks of cyanotic flushing, edema, hypotension, watery diarrhea, wheezing | Carcinoid tumor | 24-hour urine 5-hydroxyindoleacetic acid; certain foods may cause false-positive results; if elevated, the tumor must be localized using radiologic imaging |
| Anxiety, diarrhea, exophthalmos, heat intolerance, tachycardia, tremor | Hyperthyroidism | Thyroid-stimulating hormone |
| Cough, fever, high-risk sexual activity, history of exposure to tuberculosis, immunocompromise, intravenous drug use, Janeway lesions, new heart murmur, Osler nodes, splinter hemorrhages, travel, weight loss | Endocarditis HIV Tuberculosis | Complete blood count, purified protein derivative or interferon-gamma release assay, chest radiography, HIV test (CD4+ count if known to be HIV-positive), blood cultures to include HACEK organisms, echocardiography |
| Diabetes mellitus, episodic sweating | Hyper-/hypoglycemia | Test blood glucose during typical episode |
| Erectile dysfunction, low libido | Male hypogonadism | Early-morning total testosterone level |
| Excessive daytime sleepiness, Mallampati III or IV oropharynx, observed snoring or gasping during sleep, overweight | Obstructive sleep apnea | Sleep study |
| Firm lymphadenopathy without recent infection | Malignancy | Lymph node biopsy |
| Generalized sweating, headache, labile hypertension, paroxysms of palpitations | Pheochromocytoma | 24-hour urine catecholamines or metanephrines, plasma; if elevated, the tumor must be localized using radiologic imaging |
| Heartburn, indigestion | Gastroesophageal reflux disease | Trial of proton pump inhibitor or histamine H2 blocker |
| Upper respiratory tract infection | Infectious mononucleosis | Complete blood count, heterophile antibodies (consider antiviral capsid antigen immune globulin M) |
| Women age 30s to 60s, menstrual changes, vasomotor symptoms | Perimenopause/menopause | Follicle-stimulating hormone (may be normal at early stage), treatment of vasomotor symptoms |